Phase III topline results announced for the COVID-19 booster vaccine candidate
Hørsholm, Denmark, 27 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for ABNCoV2, a capsid virus-like particle (cVLP) based non-adjuvanted COVID-19 booster vaccine. Bavarian Nordic reports that the booster study successfully met its primary endpoint, demonstrating non-inferiority to mRNA-vaccine, and that the regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third quarter of 2023.
CEO Bent Frandsen comments:
“Bavarian Nordic’s reporting of meeting the primary endpoint in the Phase III clinical trial for ABNCoV2, their COVID-19 booster vaccine, is great. We look forward to seeing the secondary endpoints soon. It is worth noting, that the landscape for COVID-19 vaccine is very dynamic, but we see a clear validation of our ExpreS2™ antigen production system in combination with the VLP technology from AdaptVac, and the non-inferiority of ABNCoV2 to a state-of-the art mRNA vaccine.”
Bavarian Nordic expects results from the Phase III clinical trial secondary endpoints in third quarter 2023. Additional information can be found in the press release published today by Bavarian Nordic:
https://www.bavarian-nordic.com/investor/news/news.aspx?news=6807
About the cVLP COVID-19 vaccine product, ABNCoV2
Under the PREVENT-NCoV consortium, ExpreS2ion and its 34%-owned associate company AdaptVac have applied their unique Drosophila S2 insect cell protein production technology, ExpreS2™, and capsid virus-like particle (VLP) COVID-19 technology, respectively, to develop a novel next-generation COVID-19 vaccine, known as ABNCoV2. Bavarian Nordic has licensed the global commercialization rights to the ABNCoV2 COVID-19 vaccine and variants hereof. In the Bavarian Nordic-sponsored Phase II clinical trial, ABNCoV2 demonstrated a significant boost to the neutralizing antibodies against all tested variants, including the Omicron variants. Furthermore, six months post vaccination, neutralization titers were six times higher than pre-boost titers against Wuhan and nearly ten times higher than the pre-boost titers for Omicron BA.1. Compared to the data published for mRNA vaccines, the antibody decay appears less sharp, indicating a potentially longer duration of protection across variants of concern, which has been further evidenced in the twelve months post vaccination data.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out below, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
Email: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS™, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS™ is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Tags: